CompletedPhase 3ACTRN12610000134022

An international multi-centre study of tamoxifen vs placebo in women at increased risk of breast cancer.

A multicentre trial of Tamoxifen to prevent breast cancer in women at increased risk of breast cancer.

Sponsor

Queen Mary University of London

Enrollment

7,000 participants

Start Date

Dec 1, 1992

Study Type

Interventional

Conditions

Prevention of Breast cancer

Summary

A study to evaluate the reduction in incidence of, and mortality from, breast cancer associated with taking tamoxifen daily for five years

Eligibility

Sex: FemalesMin Age: 45 YearssMax Age: 70 Yearss

Plain Language Summary

Simplified for easier understanding

This large international study tests whether the medication tamoxifen can help prevent breast cancer in women who are at higher risk due to family history or previous breast biopsy results. Women aged 35 to 70 who meet specific risk criteria may be eligible.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Arm A: Tamoxifen 20 mg/day tablet orally for 5 years

Locations(1)

New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12610000134022